Clinical Application of Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitors against Non-Small Cell Lung Cancer

MedUnion submitted, created time 1 year 8 months (www.mupnet.com)

Single-agent epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib or erlotinib, have a response rate of 20-30% against NSCLC in East Asians who have received prior chemotherapy, while the response rate was only ~10% in unselected white patients. In addition to East Asian populations who have a higher response rate, the response rates are higher in women, persons with adenocarcinoma, and those who have never smoked. These findings can be partly explained by the higher incidence of EGFR mutations in these groups of patients with NSCLC

Submit comment | Blog It | Email It | Keywords: carcinoma non-small cell lung chemotherapy epidermal growth factor receptor tyrosine kinase inhibitor

Tyrosine kinase inhibitor SU6668 represses chondrosarcoma growth via antiangiogenesis in vivo

freeman submitted, created time 1 year 9 months (www.biomedcentral.com)

As chondrosarcomas are resistant to chemotherapy and ionizing radiation, therapeutic options are limited. Radical surgery often cannot be performed. Therefore, additional therapies such as antiangiogenesis represent a promising strategy for overcoming limitations in chondrosarcoma therapy. SU6668 is a potent inhibitor of chondrosarcoma tumor growth in vivo. This effect appears to be induced by the antiangiogenic effects of SU6668, which are mediated by the inhibition of the key angiogenic receptor tyrosine kinases Flk-1/KDR, PDGFRbeta and FGFR1

Submit comment | Blog It | Email It | Keywords: Tyrosine kinase inhibitor SU6668 chondrosarcoma antiangiogenesis